Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
Location status: Recruiting
NCT Number: NCT03002272
In this observational study, the investigators will enroll subjects who underwent TAVR or SAVR more than 3 years ago. Clinical and procedural data from the implant/surgery will be collected, alongside clinical and echocardiographic data from subsequent follow-up visits.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Washington D.C., District of Columbia, 20010, United States
Location status: Recruiting
There is limited available information on long term TAVR valve function. In this observational study, the investigators will enroll subjects who underwent TAVR or SAVR more than 3 years ago. Clinical and procedural data from the implant/surgery will be collected, alongside clinical and echocardiographic data from subsequent follow-up visits. Up-to-date echocardiography will be performed and analyzed in a Core Lab to assess valve function yearly.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for TAVR subjects
a) TAVR performed more than 3 years ago
Exclusion criteria
Inclusion criteria
for SAVR subjects
Exclusion criteria
for SAVR subjects e) Subjects unable to consent to participate, unless the subject has a legally authorized representative f) Subjects unwilling to participate g) Subject has undergone re-intervention to prosthetic aortic valve since TAVR procedure (e.g. balloon valvuloplasty, SAVR, re-do TAVR, paravalvular leak closure) h) Echocardiographic evidence of prosthetic valve dysfunction within first 3 years post-SAVR (mean aortic gradient ≥20mmHg AND/OR moderate-severe transvalvular aortic regurgitation)
subjects that underwent TAVR more than 3 years ago
Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
Time frame: 7 years
Mean aortic valve gradient ≥20 mm Hg Moderate-severe transvalvular aortic regurgitation
Time frame: discharge from hospital
Change in functional status from baseline and discharge per NYHA classification
Time frame: upto 7 years
Increase in severity of aortic regurgitation by one or more grading of severity
Contact information is provided by the study sponsor or research team.
Medstar Health Research Institute
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07625033
Anesthesia, Aortic Valve Replacement
Metz, France
View Trial DetailsNCT04722250
Aortic Valve Disease, Aortic Valve Replacement
La Jolla, California, United States
View Trial DetailsNCT05404880
Aortic Valve Replacement
Hefei, Anhui, China
View Trial DetailsNCT05404100
Aortic Valve Disease, Aortic Valve Replacement
Copenhagen O, Denmark
View Trial Details